抗原负载的DC-CIK联合化疗治疗晚期恶性黑色素瘤的临床研究

Clinical study on DC-CIK loaded with antigen combined with chemotherapy in the treatment of end-stage malignant melanoma

目的:研究抗原负载的DC-CIK过继免疫疗法联合化疗对晚期恶性黑色素瘤的临床疗效。方法:选取郑州大学第一附属医院收治的60例晚期恶性黑色素瘤患者,28例行抗原负载的DC-CIK联合化疗(A组),32例行单纯化疗(B组),对两组患者治疗后免疫功能、生活质量、中位生存期及无进展生存期进行比较。结果:A组治疗后外周血中CD3+,CD3+/CD4+,CD3+/CD8+,CD4+/CD8+和CD16+/CD56+细胞比值无明显变化,(P>0.05);B组治疗后外周血中T细胞亚群比例较之前显著下降,(P<0.05)。A组行细胞回输结束后,QOL评分改善比例为57.1%,与B组改善率31.2%而言,(P<0.05)比较差异有统计学意义;A组患者的无进展生存期(月)较B组患者长(16vs9,P<0.05),A组与B组患者的总生存期,比较差异无统计学意义(P>0.05)。结论:抗原负载的DC-CIK细胞联合化疗治疗晚期恶性黑色素瘤安全有效,在提高患者免疫功能、减轻化疗不良反应、延长无进展生存期和改善患者生活质量方面具有重要作用。

Objective To evaluate the therapeutic effect of dendritic cells-cytokine icduced killers cells(DC-CIK) loaded with antigen chemotherapy in the treatment of end-stage malignant melanoma(MM).Methods 60 MM patients were selected from the First Affiliated Hospital of Zhengzhou University. 28 of them were treated by DC-CIK loaded with antigen with chemotherapy(A group), and another 32 were treated by chemotherapy only(B group). The immune function, quality of life(QOL), the median progression-free survival(m PFS) and overall survival(OS) of the patients were compared between the two groups after the treatment. Results There was no obvious change of the ratio of CD3+, CD3+/CD4+,CD3+/CD8+, CD4+/CD8+and CD16+/CD56+in the peripheral blood of group A(P>0.05), while T cell subsets decreased significantly after the treatment of group B, and obviously lower than that of group A(P<0.05).57.1% of patients in group A were improved in their quality of life, significantly higher than that of B group, which was 31.2%(P<0.05). The median progression-free survival(m PFS) of group A was longer than that of group B(16 months vs 9 months,P<0.05),while the median overall survival(OS) of the two groups had no significant difference(P >0.05). Conclusions Treatment with DC-CIK adoptive immunotherapy combined with chemotherapy can improve effectively the immune function and reduced the side effects of chemotherapy, prolong the PFS, and improve QOL of end-stage MM patients.